AI-Driven Platforms Enhance Drug Discovery Collaborations

Generative AI gained significant attention in 2022 with the launch of ChatGPT, showcasing its impressive text-generation capabilities. This technology is poised to revolutionise drug discovery, attracting substantial investments and driving collaborations within the biopharma industry.

Dealmaking with AI-focused companies such as major biopharma companies are forming partnerships with AI-driven firms to develop antibodies and small molecules. Deals include Almirall’s partnership with Absci (worth up to $650 million) and AstraZeneca’s collaboration with Absci ($247 million).

Key Players in AI-driven therapeutics companies like Generate, Absci, BigHat Biosciences, BioMap, and Aqemia are leading the charge, using AI to target hard-to-drug proteins and develop biologics and small molecules.

The success of AI-designed small molecules in clinical trials will be closely monitored to determine if AI can not only accelerate drug discovery but also improve clinical outcomes. 

For more info on the generative AI in drug discovery and development within the biopharma industry, view the full article here.

To reach and collaborate with potential partners and investors for your drug discovery, contact us about advertising with Biopharma Dealmakers.

About Biopharma Dealmakers

Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles. 

The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.